Metal-Organic Framework Traps with Record-High Bilirubin Removal Capacity for Hemoperfusion Therapy
Metal-Organic Framework Traps with Record-High Bilirubin Removal Capacity for Hemoperfusion Therapy
复制标题
DOI：
10.1021/acsami.0c03859
复制
发表时间：
2020-06-10
影响因子：
9.5
通讯作者：
Zhang, Lei
中科院分区：
文献类型：
--
作者：
Li, Qingsi;Zhao, Weiqiang;Zhang, Lei
基于吸附的血液灌流已被广泛用于清除急性肝功能衰竭（ALF）患者血液中的毒素。然而，临床上常用的多孔吸附剂，如活性炭（AC）和吸附树脂的吸附性能不理想，严重阻碍了其解毒效果。本文中，引入两种基于笼的金属有机框架（MOF），PCN-333（由4，4，4-均三嗪-2，4，6-三基-三苯甲酸（H（3）TATB）配体和Al-3金属簇构成）和MOF-808（由1，3，5-苯三羧酸（H3BTC）配体和Zr-6金属簇构成）用于高效血液灌流。它们具有可忽略不计的溶血活性，可以作为"胆红素陷阱"，以实现对胆红素（一种与ALF相关的典型毒素）的出色吸附性能。值得注意的是，PCN-333显示出在先前报道的各种胆红素吸附剂中创纪录的高吸附容量（类似于1003.8 mg g（-1））。更重要的是，由于它们的高选择性，它们可以有效地吸附牛血清白蛋白（BSA）溶液甚至100%胎牛血清（FBS）中的胆红素。值得注意的是，生物溶液中PCN-333的吸附速率和容量分别比临床AC快约4倍和69倍。这项工作的发现为克服血液灌流治疗中低吸附效率和容量的挑战铺平了新的途径。
Adsorption-based hemoperfusion has been widely used to remove toxins from the blood of patients suffering acute liver failure (ALF). However, its detoxification effect has been severely hampered by the unsatisfactory adsorption performance of clinically used porous adsorbents, such as activated carbon (AC) and adsorption resin. Herein, two cage-based metal-organic frameworks (MOFs), PCN-333 (constructed from 4,4,4-s-triazine-2,4,6-triyl-tribenzoic acid (H(3)TATB) ligands and Al-3 metal clusters) and MOF-808 (constructed from 1,3,5-benzenetricarboxylic acid (H3BTC) ligands and Zr-6 metal clusters), are introduced for highly efficient hemoperfusion. They possess negligible hemolytic activity and can act as "bilirubin traps" to achieve outstanding adsorption performance toward bilirubin, a typical toxin related to ALF. Notably, PCN-333 shows a record-high adsorption capacity (similar to 1003.8 mg g(-1)) among various bilirubin adsorbents previously reported. More importantly, they can efficiently adsorb bilirubin in bovine serum albumin (BSA) solution or even in 100% fetal bovine serum (FBS) due to their high selectivity. Strikingly, the adsorption rate and capacity of PCN-333 in biological solutions are approximately four times faster and 69 times higher than those of clinical AC, respectively. Findings in this work pave a new avenue to overcome the challenge of low adsorption efficiency and capacity in hemoperfusion therapy.